{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:43:23Z","timestamp":1793025803626,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012956","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000}}],"reference-count":344,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012956.pub2","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T14:00:52Z","timestamp":1668434452000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Pharmacological interventions for people with borderline personality disorder"],"prefix":"10.1002","volume":"2022","author":[{"given":"Jutta M","family":"Stoffers-Winterling","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy; University Medical Center Mainz; Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Jakob","family":"Storeb\u00f8","sequence":"additional","affiliation":[{"name":"Psychiatric Research Unit; Psychiatry Region Zealand; Slagelse Denmark"},{"name":"Child and Adolescent Psychiatric Department; Region Zealand; Roskilde Denmark"},{"name":"Department of Psychology; University of Southern Denmark; Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Pereira Ribeiro","sequence":"additional","affiliation":[{"name":"Psychiatric Research Unit; Psychiatry Region Zealand; Slagelse Denmark"},{"name":"Department of Psychology; University of Southern Denmark; Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickey T","family":"Kongerslev","sequence":"additional","affiliation":[{"name":"Department of Psychology; University of Southern Denmark; Odense Denmark"},{"name":"District Psychiatric Services Roskilde; Region Zealand Mental Health Services; Roskilde Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit A","family":"V\u00f6llm","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, Center for Neurology; University Rostock; Rostock Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica T","family":"Mattivi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy; University Medical Center Mainz; Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlend","family":"Faltinsen","sequence":"additional","affiliation":[{"name":"Psychiatric Research Unit; Psychiatry Region Zealand; Slagelse Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Todorovac","sequence":"additional","affiliation":[{"name":"Psychiatric Research Unit; Psychiatry Region Zealand; Slagelse Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie S","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Psychiatric Research Unit; Psychiatry Region Zealand; Slagelse Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette E","family":"Callesen","sequence":"additional","affiliation":[{"name":"Psychiatric Research Unit; Psychiatry Region Zealand; Slagelse Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian P","family":"Sales","sequence":"additional","affiliation":[{"name":"Duncan MacMillan House; Nottinghamshire Healthcare NHS Foundation Trust; Nottingham UK"},{"name":"Institute of Mental Health; Department of Psychiatry & Applied Psychology; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Perrine","family":"Schaug","sequence":"additional","affiliation":[{"name":"Region Zealand Psychiatry; Center for Evidence Based Psychiatry; Slagelse Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Simonsen","sequence":"additional","affiliation":[{"name":"Research Unit, Mental Health Services, Copenhagen University Hospital; Psychiatry Region Zealand; Roskilde Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Lieb","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy; University Medical Center Mainz; Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD012956.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1177\/070674371305800705","article-title":"Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial","volume":"58","author":"Amminger","year":"2013","journal-title":"Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/archgenpsychiatry.2009.192","article-title":"Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial","volume":"67","author":"Amminger","year":"2010","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0003|cit3","unstructured":"Verkes Borderline Study: the effect of quetiapine on borderline personality disordered patients clinicaltrials.gov\/ct2\/show\/NCT00254748"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD012956.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"S425","DOI":"10.1016\/S0924-977X(08)70622-9","article-title":"P.3.c.038. The effect of quetiapine on psychotic-like symptoms in borderline personality disorder. A placebo-controlled trial","volume":"18","author":"Van den Broek","year":"2008","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0005|cit5","first-page":"296","article-title":"Omega-3 fatty acids associated with valproate in the treatment of borderline personality disorder: a controlled study","volume":"19","author":"Bellino","year":"2013","journal-title":"Journal of Psychopathology"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/0269881113510072","article-title":"Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid","volume":"28","author":"Bellino","year":"2014","journal-title":"Journal of Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40261-017-0617-x","article-title":"Combination of omega-3 fatty acids and valproic acid in treatment of borderline personality disorder: a follow-up study","volume":"38","author":"Bozzatello","year":"2018","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0008|cit8","unstructured":"Bellino S Inclusion of study in Cochrane review Email to: A Tadorovac"},{"issue":"11","key":"10.1002\/14651858.CD012956.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1176\/appi.ajp.2014.13101348","article-title":"Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial","volume":"171","author":"Black","year":"2014","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0010|cit10","first-page":"4","article-title":"Quetiapine's effect on the SCL-90-R domains in patients with borderline personality disorder","volume":"28","author":"Lee","year":"2016","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0011|cit11","unstructured":"Seroquel extended release (XR) for the management of borderline personality disorder (BPD) clinicaltrials.gov\/ct2\/show\/NCT00880919"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4088\/jcp.v65n0118","article-title":"Olanzapine versus placebo in the treatment of borderline personality disorder","volume":"65","author":"Bogenschutz","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0013|cit13","unstructured":"Nurnberg HG Bogenschutz MP Atypical antipsychotic treatment of BPD: a 12-week, double-blind, placebo-control trial with olanzapine 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Fransisco (CA) 2003"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0014|cit14","unstructured":"Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: a randomized controlled trial www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=365182"},{"issue":"9","key":"10.1002\/14651858.CD012956.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40263-017-0458-4","article-title":"Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: an open-label randomized controlled trial","volume":"31","author":"Bozzatello","year":"2017","journal-title":"Central Nervous System Drugs"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1001\/archpsyc.1988.01800260015002","article-title":"Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine","volume":"45","author":"Cowdry","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1176\/ajp.142.1.98","article-title":"Alprazolam-induced dyscontrol in borderline personality disorder","volume":"142","author":"Gardner","year":"1985","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00004714-198608000-00008","article-title":"Development of melancholia during carbamazepine treatment in borderline personality disorder","volume":"6","author":"Gardner","year":"1986","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1176\/ajp.143.4.519","article-title":"Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder","volume":"143","author":"Gardner","year":"1986","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s13063-015-0823-x","article-title":"Lamotrigine versus inert placebo in the treatment of borderline personality disorder: study protocol for a randomized controlled trial and economic evaluation","volume":"16","author":"Crawford","year":"2015","journal-title":"Trials"},{"issue":"17","key":"10.1002\/14651858.CD012956.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22170","article-title":"Lamotrigine for people with borderline personality disorder: a RCT","volume":"22","author":"Crawford","year":"2018","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0022|cit22","unstructured":"Crawford MJ Inclusion of your study in Cochrane review Email to: A Pathmanathan Ratnam"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/0924-977x(94)90296-8","article-title":"A trial of carbamazepine in borderline personality disorder","volume":"4","author":"De la Fuente","year":"1994","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/0924-977X(93)90132-6","article-title":"Carbamazepine in borderline personality disorder","volume":"3","author":"De la Fuente","year":"1993","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"442","DOI":"10.4088\/jcp.v63n0511","article-title":"Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study","volume":"63","author":"Frankenburg","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD012956.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1001\/archpsyc.1986.01800070070009","article-title":"Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo","volume":"43","author":"Goldberg","year":"1986","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1192\/bjp.2021.159","article-title":"A double-blind placebo-controlled study of brexpiprazole for the treatment of borderline personality disorder","volume":"220","author":"Grant","year":"2022","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1192\/bjp.bp.106.022707","article-title":"Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial","volume":"190","author":"Hallahan","year":"2007","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4088\/jcp.v62n0311","article-title":"A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder","volume":"62","author":"Hollander","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0030|cit30","first-page":"544","article-title":"The effect of olanzapine and sertraline on personality disorder in patients with methadone maintenance therapy","volume":"22","author":"Jariani","year":"2010","journal-title":"Psychiatria Danubina"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40263-018-0506-8","article-title":"Effect of the glutamate NMDA receptor antagonist memantine as adjunctive treatment in borderline personality disorder: an exploratory, randomised, double-blind, placebo-controlled trial","volume":"32","author":"Kulkarni","year":"2018","journal-title":"Central Nervous System Drugs"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0032|cit32","unstructured":"Re: Your Request Email to: A Pathmanatan Ratnam"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0033|cit33","unstructured":"A novel drug for borderline personality disorder clinicaltrials.gov\/ct2\/show\/study\/NCT02097706"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0034|cit34","first-page":"148","article-title":"Response of borderline patients to loxapine and chlorpromazine","volume":"43","author":"Leone","year":"1982","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0035|cit35","unstructured":"Linehan M Update on dialectical behavioral therapy for BPD 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta (GA) 2005"},{"issue":"9","key":"10.1002\/14651858.CD012956.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"999","DOI":"10.4088\/jcp.v69n0617","article-title":"Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study","volume":"69","author":"Linehan","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/01.jcp.0000195113.61291.48","article-title":"Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study","volume":"26","author":"Loew","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/JCP.0b013e318173a8fb","article-title":"Topiramate treatment of women with borderline personality disorder, part II: an open 18-month follow-up","volume":"28","author":"Loew","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0039|cit39","first-page":"263","volume-title":"Impulsivity and Aggression","author":"Markovitz","year":"1995"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0040|cit40","first-page":"255","article-title":"Efficacy of extended-release divalproex combined with \"condensed\" dialectical behavior therapy for individuals with borderline personality disorder","volume":"24","author":"Moen","year":"2012","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0041|cit41","unstructured":"Depakote ER in borderline personality disorder clinicaltrials.gov\/ct2\/show\/NCT00222482"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0165-0327(82)90026-x","article-title":"Pharmacological prevention of suicidal behaviour","volume":"4","author":"Montgomery","year":"1982","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0043|cit43","unstructured":"Montgomery SA Montgomery DB Janyanthi Rani S Roy DH Shaw PJ McAuley R Maintenance therapy in repeat suicidal behaviour: a placebo controlled trial 10th International Congress for Suicide Prevention and Crisis Intervention; 1979 Jun 17-20; Ottawa (ON) 1979"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/B978-0-08-027080-7.50130-0","volume-title":"Depression and Suicide: Aspects Medicaux, Psychologiques et Socio-Culturels","author":"Montgomery","year":"1983"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0165-0327(82)90026-x","article-title":"Pharmacological prevention of suicidal behaviour","volume":"4","author":"Montgomery","year":"1982","journal-title":"Journal of Affective Disorders"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012956.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2125.1983.tb05864.x","article-title":"The prevention of recurrent suicidal acts","volume":"15","author":"Montgomery","year":"1983","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000329700","article-title":"Higher executive control and visual memory performance predict treatment completion in borderline personality disorder","volume":"81","author":"Fertuck","year":"2012","journal-title":"Psychotherapy and Psychosomatics"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0048|cit48","unstructured":"Treating suicidal behavior and self-mutilation in people with borderline personality disorder clinicaltrials.gov\/ct2\/show\/results\/NCT00533117?sect=X043716&view=results#part"},{"issue":"7","key":"10.1002\/14651858.CD012956.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s00406-007-0735-1","article-title":"Topiramate reduced aggression in female patients with borderline personality disorder","volume":"257","author":"Nickel","year":"2007","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"11","key":"10.1002\/14651858.CD012956.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.4088\/jcp.v65n1112","article-title":"Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study","volume":"65","author":"Nickel","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eurpsy.2007.09.004","article-title":"Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up","volume":"23","author":"Nickel","year":"2008","journal-title":"European Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.biopsych.2004.11.044","article-title":"Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study","volume":"57","author":"Nickel","year":"2005","journal-title":"Biological Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/00048670701261251","article-title":"Topiramate treatment of aggression in male borderline patients","volume":"41","author":"Nickel","year":"2007","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00213-007-0740-0","article-title":"Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up","volume":"191","author":"Nickel","year":"2007","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1176\/ajp.2006.163.5.833","article-title":"Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study","volume":"163","author":"Nickel","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD012956.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.4088\/jcp.v68n1124f","article-title":"Aripiprazole treatment of patients with borderline personality disorder","volume":"68","author":"Nickel","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0057|cit57","unstructured":"Ziprasidone in the treatment of borderline personality disorder clinicaltrials.gov\/ct2\/show\/NCT00635921"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4088\/JCP.v69n0412","article-title":"Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study","volume":"69","author":"Pascual","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0059|cit59","unstructured":"Study of lamotrigine treatment of affective instability in borderline personality disorder clinicaltrials.gov\/ct2\/show\/NCT00634062"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/YIC.0b013e32832d6c2f","article-title":"A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder","volume":"24","author":"Reich","year":"2009","journal-title":"International Clinical Psychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD012956.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1176\/appi.ajp.159.12.2048","article-title":"SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder","volume":"159","author":"Rinne","year":"2002","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00004714-199502000-00005","article-title":"Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder","volume":"15","author":"Salzmann","year":"1995","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0063|cit63","unstructured":"Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder clinicaltrials.gov\/ct2\/show\/NCT01133301"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/YIC.0b013e32834d0e50","article-title":"Evaluation of naltrexone for dissociative symptoms in borderline personality disorder","volume":"27","author":"Schmahl","year":"2012","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0065|cit65","unstructured":"Naltrexone in borderline personality disorder clinicaltrials.gov\/ct2\/show\/NCT00124839"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0066|cit66","unstructured":"Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder clinicaltrials.gov\/ct2\/show\/record\/NCT01133301"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/YIC.0b013e32834d0e50","article-title":"Evaluation of naltrexone for dissociative symptoms in borderline personality disorder","volume":"27","author":"Schmahl","year":"2012","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0068|cit68","unstructured":"Efficacy and safety of olanzapine in patients with borderline personality disorder: a randomized, flexible-dose, double-blind comparison with placebo www.lillytrials.com\/results_files\/zyprexa\/zyprexa_summary_6257"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0069|cit69","unstructured":"Olanzapine in patients with borderline personality disorder clinicaltrials.gov\/ct2\/show\/NCT00091650"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012956.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1017\/S1461145706007292","article-title":"P02.101 Olanzapine for the treatment of borderline personality disorder: a flexible-dose 12-week randomized double-blind placebo-controlled study","volume":"9","author":"Schulz","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1192\/bjp.bp.107.037903","article-title":"Olanzapine for the treatment of borderline personality disorder: variable dose, 12-week randomised double-blind placebo-controlled study","volume":"193","author":"Schulz","year":"2008","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0072|cit72","doi-asserted-by":"crossref","unstructured":"Schulz SC Zanarini MC Detke HC Trzaskoma Q Lin D DeBerdt W Olanzapine for the treatment of borderline personality disorder: a flexible-dose, 12-week, randomized, double-blind, placebo-controlled study Association of European Psychiatrsts. 15th European Congress of Psychiatry; 2007 Mar 17-21; Madrid, Spain 2007","DOI":"10.1016\/j.eurpsy.2007.01.564"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012956.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.1016\/j.eurpsy.2007.01.564","article-title":"P248 Olanzapine for the treatment of borderline personality disorder: a flexible-dose 12-week randomized double-blind placebo-controlled study","volume":"22","author":"Schulz","year":"2007","journal-title":"European Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012956.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"S229","DOI":"10.1017\/S1461145706007292","article-title":"80. Olanzapine for the treatment of borderline personality disorder: two 12-week randomized double-blind placebo-controlled trials","volume":"31","author":"Zanarini","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/JCP.0b013e3181c826ff","article-title":"Olanzapine versus haloperidol in the management of borderline personality disorder","volume":"30","author":"Shafti","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"38","DOI":"10.5455\/bcp.20140923100030","article-title":"A comparative study on olanzapine and aripiprazole for symptom management in female patients with borderline personality disorder","volume":"25","author":"Shafti","year":"2015","journal-title":"Klinik Psikofarmakoloji B\u00fclteni [Bulletin of Clinical Psychopharmacology]"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/2211556003666140912223626","article-title":"Olanzapine vs aripiprazole in the management of borderline personality disorder","volume":"3","author":"Shafti","year":"2014","journal-title":"Current Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"379","DOI":"10.4088\/jcp.v65n0314","article-title":"Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder","volume":"65","author":"Simpson","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0079|cit79","unstructured":"Pascual JC Soler J Barrachina J Campins J Puigdemont D Alvarez E Olanzapine plus dialectical behavior therapy of patients with BPD Psychotherapy and Psychopharmacology: Dissolving the Mind-Brain Barrier. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York (NY) 2004"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1176\/appi.ajp.162.6.1221","article-title":"Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder","volume":"162","author":"Soler","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0081|cit81","first-page":"177","article-title":"Behavioral dyscontrol in borderline patients treated with amitriptyline","volume":"23","author":"Soloff","year":"1987","journal-title":"Psychopharmacology Bulletin"},{"issue":"12","key":"10.1002\/14651858.CD012956.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1176\/ajp.143.12.1603","article-title":"Paradoxical effects of amitriptyline on borderline patients","volume":"143","author":"Soloff","year":"1986","journal-title":"American Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD012956.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/archpsyc.1986.01800070081010","article-title":"Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo","volume":"43","author":"Soloff","year":"1986","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/00004714-198908000-00002","article-title":"Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response","volume":"9","author":"Soloff","year":"1989","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0085|cit85","first-page":"177","article-title":"Amitriptyline and haloperidol in unstable and schizotypal borderline disorders","volume":"22","author":"Soloff","year":"1986","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0086|cit86","first-page":"333","article-title":"Haloperidol vs phenelzine in continuation therapy of borderline disorder","volume":"29","author":"Cornelius","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"issue":"12","key":"10.1002\/14651858.CD012956.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1176\/ajp.150.12.1843","article-title":"Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine","volume":"150","author":"Cornelius","year":"1993","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/archpsyc.1993.01820170055007","article-title":"Efficacy of phenelzine and haloperidol in borderline personality disorder","volume":"50","author":"Soloff","year":"1993","journal-title":"Archives of General Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD012956.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/0269881107084004","article-title":"Lamotrigine treatment of aggression in female borderline patients, part II: an 18-month follow-up","volume":"22","author":"Leiberich","year":"2008","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/0269881105051540","article-title":"Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study","volume":"19","author":"Tritt","year":"2005","journal-title":"Journal of Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD012956.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4088\/jcp.v62n1103","article-title":"Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study","volume":"62","author":"Zanarini","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1176\/appi.ajp.160.1.167","article-title":"Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study","volume":"160","author":"Zanarini","year":"2003","journal-title":"American Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD012956.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"903","DOI":"10.4088\/jcp.v65n0704","article-title":"A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder","volume":"65","author":"Zanarini","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0094|cit94","unstructured":"Efficacy and safety of olanzapine in patients with borderline personality disorder: a randomized double-blind comparison with placebo www.lillytrials.com\/results_files\/zyprexa\/zyprexa_summary_6523\/"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0095|cit95","unstructured":"Efficacy and safety of olanzapine in patients with borderline personality disorder clinicaltrials.gov\/ct2\/show\/NCT00088036"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012956.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.1016\/j.eurpsy.2007.01.565","article-title":"A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo controlled study","volume":"22","author":"Zanarini","year":"2007","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Zanarini MC Schulz SC Detke HC Tanaka Y Zhao F Lin D A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study Association of European Psychiatrists. 15th European Congress of Psychiatry; 2007 Mar 17-21; Madrid, Spain 2007","DOI":"10.1016\/j.eurpsy.2007.01.564"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012956.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1017\/S1461145706007450","article-title":"P02.102 A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized double-blind placebo-controlled study","volume":"9","author":"Zanarini","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012956.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"S229","DOI":"10.1017\/S1461145706007292","article-title":"80. Olanzapine for the treatment of borderline personality disorder: two 12-week randomized double-blind placebo-controlled trials","volume":"31","author":"Zanarini","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/JCP.0b013e31819a4bae","article-title":"Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial","volume":"29","author":"Ziegenhorn","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0101|cit101","unstructured":"Investigation of the benefits of using quetiapine as an adjunct treatment in addition to psychotherapy in patients diagnosed with severe Borderline Personality Disorder www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=368589"},{"issue":"7","key":"10.1002\/14651858.CD012956.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/070674370605100707","article-title":"Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy","volume":"51","author":"Bellino","year":"2006","journal-title":"Canadian Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD012956.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/archpsyc.1997.01830240035005","article-title":"Fluoxetine and impulsive aggressive behavior in personality-disordered subjects","volume":"54","author":"Coccaro","year":"1997","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1176\/appi.ajp.162.3.621","article-title":"Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder","volume":"162","author":"Hollander","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/sj.npp.1300153","article-title":"Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders","volume":"28","author":"Hollander","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0106|cit106","unstructured":"Quetiapine versus sertraline as the pharmacological component in a standardised psychopharmacological and psychotherapeutic treatment of borderline personality disorder: a randomised, rater-blinded study www.isrctn.com\/ISRCTN11135486"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0107|cit107","unstructured":"Malevani J AW: Cochrane review: RCT zu Quetapin und Sertraline bei BPS [personal communication] Email to: J Stoffers-Winterling"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"628","DOI":"10.4088\/jcp.v64n0602","article-title":"Risperidone in the treatment of schizotypal personality disorder","volume":"64","author":"Koenigsberg","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0109|cit109","first-page":"75","article-title":"Aggressiveness and personality disorders: evaluation of efficacy and existence of predictors in the treatment with fluvoxamine and lithium","volume":"44","author":"La Malfa","year":"2003","journal-title":"Minerva Psychiatrica"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1521\/pedi.1990.4.2.173","article-title":"Lithium therapy for borderline patients: preliminary findings","volume":"4","author":"Links","year":"1990","journal-title":"Journal of Personality Disorders"},{"issue":"7","key":"10.1002\/14651858.CD012956.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.pnpbp.2006.03.010","article-title":"Personality disorders and response to medication treatment in panic disorder: a 1-year naturalistic study","volume":"30","author":"Marchesi","year":"2006","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0112|cit112","unstructured":"Goodman M New AS Koenigsberg HW Hazlett E Flory J Siever L Psychotherapy and combined treatment in BPD: possible effects Psychosomatic Medicine. Integrating Psychiatry & Medicine. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta (GA) 2005 126 7"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0113|cit113","unstructured":"Goodman M RE: [EXTERNAL] Cochrane Colllaboration review [personal communication] Email to: J Stoffers-Winterling"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0114|cit114","unstructured":"DBT and escitalopram in borderline personality disorder clinicaltrials.gov\/ct2\/show\/NCT00255554"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0115|cit115","unstructured":"Topiramate for treatment of patients with borderline personality disorder and alcohol dependence clinicaltrials.gov\/ct2\/show\/NCT00463775"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0116|cit116","unstructured":"Bloch M Re: RCT of Risperidone in borderline PD [pers commun] Email to: J. Stoffers-Winterling"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0117|cit117","unstructured":"Low-dose risperidone treatment for subjects suffering from borderline personality disorder clinicaltrials.gov\/ct2\/show\/NCT00633802"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0118|cit118","unstructured":"McCloskey M Fwd: Cochrane Collaboration review - RCT of escitalopram in BPD Email to: J Stoffers-Winterling"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0119|cit119","unstructured":"Selective serotonin reuptake inhibitors (SSRIs) in borderline personality disorder clinicaltrials.gov\/ct2\/show\/NCT01103180"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0120|cit120","unstructured":"Ketamine in borderline personality disorder clinicaltrials.gov\/ct2\/show\/NCT03395314"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0121|cit121","first-page":"524","article-title":"Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression","volume":"25","author":"Parsons","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3109\/13651501.2014.940052","article-title":"Adjunctive lithium treatment in the prevention of suicidal behavior in patients with depression and comorbid personality disorders","volume":"18","author":"Rombold","year":"2014","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"554","DOI":"10.4088\/jcp.v64n0510","article-title":"Chronic depression and comorbid personality disorders: response to sertraline versus imipramine","volume":"64","author":"Russell","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD012956.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1176\/ajp.141.11.1455","article-title":"Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol","volume":"141","author":"Serban","year":"1984","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1176\/ajp.155.4.543","article-title":"Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression","volume":"155","author":"Verkes","year":"1998","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/02698811211069108","article-title":"Clinical effects of glabellar botulinum toxin injections on borderline personality disorder: a randomized controlled trial","volume":"36","author":"Wollmer","year":"2022","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0127|cit127","unstructured":"Efficacy of omega-3 fatty acids on borderline personality disorder: a randomised, double blind clinical trial clinicaltrials.gov\/ct2\/show\/NCT00437099"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0128|cit128","unstructured":"Clinical research study to evaluate selegiline in the treatment of borderline personality disorder clinicaltrials.gov\/ct2\/show\/NCT01912391"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0129|cit129","unstructured":"Estrogen for the treatment of borderline personality disorder anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=373455"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13063-019-4040-x","article-title":"Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial","volume":"21","author":"Arteaga-Henr\u00edquez","year":"2020","journal-title":"Trials"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0131|cit131","unstructured":"Treating impulsivity in adults with probiotics (PROBIA) clinicaltrials.gov\/ct2\/show\/NCT03495375"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0132|cit132","unstructured":"VERBATIM: a randomised controlled trial of aripiprazole for the treatment of auditory verbal hallucinations in borderline personality disorder anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=371038"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/eip.12774","article-title":"Ripiprazole compared with placebo for auditory verbal hallucinations in youth with borderline personality disorder: protocol for the VERBATIM randomized controlled trial","volume":"13","author":"Chanen","year":"2019","journal-title":"Early Intervention in Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0134|cit134","unstructured":"Stellate ganglion block in patients with borderline personality disorder and posttraumatic stress disorder www.drks.de\/DRKS00015817"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0135|cit135","unstructured":"A phase IIb study to evaluate the safety and efficacy of vafidemstat in an adult borderline personality disorder population trialsearch.who.int\/?TrialID=EUCTR2020-003469-20-ES"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0136|cit136","unstructured":"Clozapine in the treatment of borderline personality disorder clinicaltrialsregister.eu\/ctr-search\/search?query=2018-002471-18\/GB"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0137|cit137","unstructured":"Clozapine in the treatment of borderline personality disorder. The CALMED study www.isrctn.com\/ISRCTN18352058"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0138|cit138","unstructured":"Memantine and borderline personality disorder trialsearch.who.int\/?TrialID=IRCT20210106049948N1"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0139|cit139","unstructured":"Effect of omega 3 fatty acid in borderline personality disorder trialsearch.who.int\/Trial2.aspx?TrialID=IRCT20210531051453N1"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0140|cit140","unstructured":"A trial of brexpiprazole in the treatment of borderline personality disorder clinicaltrials.gov\/ct2\/show\/NCT04100096"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0141|cit141","unstructured":"A study to test different doses of BI 1358894 and find out whether they reduce symptoms in people with borderline personality disorder clinicaltrials.gov\/ct2\/show\/NCT04566601"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0142|cit142","unstructured":"Caplyta in borderline personality disorder clinicaltrials.gov\/ct2\/show\/NCT05356013"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1521\/pedi_2019_33_445","article-title":"Off-label use of second-generation antipsychotics in borderline personality disorder: a survey of Italian psychiatrists","volume":"35","author":"Aguglia","year":"2021","journal-title":"Journal of Personality Disorders"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1521\/pedi_2016_30_269","article-title":"Long-term course of borderline personality disorder: a prospective 10-year follow-up study","volume":"31","author":"Alvarez-Tom\u00e1s","year":"2017","journal-title":"Journal of Personality Disorders"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eurpsy.2018.10.010","article-title":"Long-term clinical and functional course of borderline personality disorder: a meta-analysis of prospective studies","volume":"56","author":"\u00c1lvarez-Tom\u00e1s","year":"2019","journal-title":"European Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/archgenpsychiatry.2009.192","article-title":"Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial","volume":"67","author":"Amminger","year":"2010","journal-title":"Archives of General Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD012956.pub2-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"719-25","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD012956.pub2-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"726-35","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation - determinants of a recommendation\u2019s direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"329-36","DOI":"10.1016\/j.comppsych.2007.02.001","article-title":"Psychosocial impairment and treatment utilization by patients with borderline personality disorder, other personality disorders, mood and anxiety disorders, and a healthy comparison group","volume":"48","author":"Ansell","year":"2007","journal-title":"Comprehensive Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0150|cit150","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-III)","author":"American Psychiatric Association","year":"1980"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0151|cit151","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)","author":"American Psychiatric Association","year":"1987"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0152|cit152","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0153|cit153","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD012956.pub2-BIB0154|cit154","first-page":"1","article-title":"Practice guideline for the treatment of patients with borderline personality disorder","volume":"158","author":"American Psychiatric Association","year":"2001","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0155|cit155","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5)","author":"American Psychiatric Association","year":"2013"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1521\/pedi.17.1.45.24053","article-title":"Reliability and validity of the borderline personality disorder severity index","volume":"17","author":"Arntz","year":"2003","journal-title":"Journal of Personality Disorders"},{"issue":"7454","key":"10.1002\/14651858.CD012956.pub2-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1192\/bjp.bp.113.138941","article-title":"The influence of personality disorder on outcome in adolescent self-harm","volume":"207","author":"Ayodeji","year":"2015","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"401-6","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0160|cit160","first-page":"91","volume-title":"Personality Characteristics of the Personality Disordered","author":"Barrett","year":"1995"},{"issue":"9969","key":"10.1002\/14651858.CD012956.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(14)61394-5","article-title":"Treatment of personality disorder","volume":"385","author":"Bateman","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1037\/0022-006X.47.2.343","article-title":"The assessment of suicidal intention: the Scale for Suicide Ideation","volume":"47","author":"Beck","year":"1979","journal-title":"Journal of Consulting and Clinical Psychology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0164|cit164","unstructured":"Bellino S Inclusion of study in Cochrane review Email to: A Tadorovac"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"295-302","DOI":"10.1176\/appi.ajp.158.2.295","article-title":"Treatment utilization by patients with personality disorders","volume":"158","author":"Bender","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0166|cit166","doi-asserted-by":"publisher","first-page":"254-7","DOI":"10.1176\/appi.ps.57.2.254","article-title":"Prospective assessment of treatment use by patients with personality disorders","volume":"57","author":"Bender","year":"2006","journal-title":"Psychiatric Services"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0197-2456(96)00014-1","article-title":"Uncertainty of the time of first significance in random effects cumulative meta-analysis","volume":"17","author":"Berkey","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"12","key":"10.1002\/14651858.CD012956.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00005053-198612000-00004","article-title":"Development, reliability, and validity of a dissociation scale","volume":"174","author":"Bernstein","year":"1986","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0169|cit169","doi-asserted-by":"crossref","unstructured":"Bero L Why the Cochrane risk of bias tool should include funding source as a standard item Cochrane Database of Systematic Reviews 2013 12 ED000075 10.1002\/14651858.ED000075 24575439","DOI":"10.1002\/14651858.ED000075"},{"issue":"7","key":"10.1002\/14651858.CD012956.pub2-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/070674371506000702","article-title":"The lifetime course of borderline personality disorder","volume":"60","author":"Biskin","year":"2015","journal-title":"Canadian Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD012956.pub2-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1176\/appi.ajp.2014.13101348","article-title":"Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial","volume":"171","author":"Black","year":"2014","journal-title":"American Journal of Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD012956.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s10198-016-0858-2","article-title":"Health care costs of borderline personality disorder and matched controls with major depressive disorder: a comparative study based on anonymized claims data","volume":"18","author":"Bode","year":"2017","journal-title":"European Journal of Health Economics"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/S0140-6736(21)00476-1","article-title":"Borderline personality disorder","volume":"398","author":"Bohus","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0174|cit174","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009353.pub2","article-title":"Crisis interventions for people with borderline personality disorder","author":"Borschmann","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.euroneuro.2015.03.017","article-title":"Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders","volume":"25","author":"Bridler","year":"2015","journal-title":"European Neuropsychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD012956.pub2-BIB0176|cit176","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0177|cit177","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analysis may be inconclusive -- trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses","volume":"38","author":"Brok","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD012956.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1017\/S0033291716003603","article-title":"Neuroscience-based nomenclature: improving clinical and scientific terminology in research and clinical psychopharmacology","volume":"47","author":"Br\u00fchl","year":"2017","journal-title":"Psychological Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"140-50","DOI":"10.1016\/j.jclinepi.2012.04.012","article-title":"GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence","volume":"66","author":"Brunetti","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.encep.2014.10.008","article-title":"Mental health service utilization among borderline personality disorder inpatients","volume":"41","author":"Cailhol","year":"2015","journal-title":"L'Enc\u00e9phale"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fpsyt.2019.00292","article-title":"Preliminary evidence for the cognitive model of auditory verbal hallucinations in youth with borderline personality disorder","volume":"10","author":"Cavelti","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.copsyc.2020.07.003","article-title":"Psychotic symptoms in borderline personality disorder: developmental aspects","volume":"37","author":"Cavelti","year":"2021","journal-title":"Current Opinion in Psychology"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11920-011-0242-y","article-title":"Developmental pathways to borderline personality disorder","volume":"14","author":"Chanen","year":"2012","journal-title":"Current Psychiatry Reports"},{"issue":"54","key":"10.1002\/14651858.CD012956.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"s24","DOI":"10.1192\/bjp.bp.112.119180","article-title":"Prevention and early intervention for borderline personality disorder: current status and recent evidence","volume":"Supplement","author":"Chanen","year":"2013","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wps.20429","article-title":"Prevention and early intervention for borderline personality disorder: a novel public health priority","volume":"16","author":"Chanen","year":"2017","journal-title":"World Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0186|cit186","first-page":"S44","article-title":"Development of neuropharmacologically-based behavioral assessments of impulsive aggressive behavior","volume":"3","author":"Coccaro","year":"1991","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0187|cit187","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jpsychires.2020.01.007","article-title":"The Overt Aggression Scale Modified (OAS-M) for clinical trials targeting impulsive aggression and intermittent explosive disorder: validity, reliability, and correlates","volume":"124","author":"Coccaro","year":"2020","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1192\/bjp.188.5.423","article-title":"Prevalence and correlates of personality disorder in Great Britain","volume":"188","author":"Coid","year":"2006","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0189|cit189","unstructured":"Crawford M Inclusion of your study in Cochrane review Email to: A Pathmanathan Ratnam"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0190|cit190","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1001\/jamapsychiatry.2016.4287","article-title":"Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis","volume":"74","author":"Cristea","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0191|cit191","unstructured":"Copenhagen Trial Unit TSA - Trial Sequential Analysis www.ctu.dk\/tsa"},{"issue":"15","key":"10.1002\/14651858.CD012956.pub2-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1002\/sim.1207","article-title":"Meta-analysis combining parallel and cross-over clinical trials. III: the issue of carry-over","volume":"21","author":"Curtin","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0193|cit193","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021), Cochrane 2021 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0194|cit194","volume-title":"The Use of Psychological Testing for Treatment Planning and Outcome Assessment","author":"Derogatis","year":"1994"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0195|cit195","volume-title":"S2-Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1: Behandlungsleitlinie Pers\u00f6nlichkeitsst\u00f6rungen [S2 Practical Guidelines in Psychiatry and Psychotherapy. Treatment Guideline Personality Disorders]","volume":"1","author":"Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie Psychosomatik und Nervenheilkunde (DGPPN) [German Association for Psychiatry","year":"2009"},{"issue":"19","key":"10.1002\/14651858.CD012956.pub2-BIB0196|cit196","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0197|cit197","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.copsyc.2017.09.001","article-title":"Personality disorders: community prevalence and socio-demographic correlates","volume":"21","author":"Eaton","year":"2018","journal-title":"Current Opinion in Psychology"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0199|cit199","unstructured":"Efficacy and safety of olanzapine in patients with borderline personality disorder: a randomized, flexible-dose, double-blind comparison with placebo [Summary ID #6257. Clinical Study Summary: F1D-MC-HGKL] www.lillytrials.com\/results_files\/zyprexa\/zyprexa_summary_6257"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0200|cit200","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.psc.2018.07.008","article-title":"Community and clinical epidemiology of borderline personality disorder","volume":"41","author":"Ellison","year":"2018","journal-title":"Psychiatric Clinics of North America"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The Global Assessment scale: a procedure for measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0202|cit202","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1017\/S0954579409990198","article-title":"A developmental, mentalization-based approach to the understanding and treatment of borderline personality disorder","volume":"21","author":"Fonagy","year":"2009","journal-title":"Development and Psychopathology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"i3507","DOI":"10.1136\/bmj.i3507","article-title":"When and how to update systematic reviews: consensus and checklist","volume":"354","author":"Garner","year":"2016","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD012956.pub2-BIB0204|cit204","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-021-00855-4","article-title":"Pharmacological treatments for borderline personality disorder: a systematic review and meta-analysis","volume":"35","author":"Gartlehner","year":"2021","journal-title":"Central Nervous System Drugs"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0205|cit205","first-page":"1335","article-title":"Authors\u2019 reply to Pereira Ribeiro et al: comment on \u201cPharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis\u201d","volume":"35","author":"Gartlehner","year":"2021","journal-title":"Central Nervous System Drugs"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0206|cit206","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11920-011-0249-4","article-title":"Suicidal risk and management in borderline personality disorder","volume":"14","author":"Goodman","year":"2012","journal-title":"Current Psychiatry Reports"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0207|cit207","unstructured":"GRADEpro GDT (guideline development tool) Grade Working Group, McMaster University and Evidence Prime 2021"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4088\/JCP.v69n0404","article-title":"Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions","volume":"69","author":"Grant","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0209|cit209","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1023\/A:1012779403943","article-title":"Meausrement of deliberate self-harm: preliminary data on the deliberate self-harm inventory","volume":"23","author":"Gratz","year":"2001","journal-title":"Journal of Psychopathology and Behavioral Assessment"},{"issue":"21","key":"10.1002\/14651858.CD012956.pub2-BIB0210|cit210","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMcp1007358","article-title":"Borderline personality disorder","volume":"364","author":"Gunderson","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD012956.pub2-BIB0211|cit211","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/archgenpsychiatry.2011.37","article-title":"Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study","volume":"68","author":"Gunderson","year":"2011","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0212|cit212","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1207\/S15327752JPA7703_08","article-title":"Development and initial validation of the Self-Harm Behavior Questionnaire","volume":"77","author":"Guttierez","year":"2001","journal-title":"Journal of Personality Assessment"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0213|cit213","doi-asserted-by":"publisher","first-page":"383-94","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0214|cit214","doi-asserted-by":"publisher","first-page":"395-400","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0215|cit215","doi-asserted-by":"publisher","first-page":"407-15","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD012956.pub2-BIB0216|cit216","doi-asserted-by":"publisher","first-page":"1277-82","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence - publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD012956.pub2-BIB0217|cit217","doi-asserted-by":"publisher","first-page":"1283-93","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence - imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD012956.pub2-BIB0218|cit218","doi-asserted-by":"publisher","first-page":"1294-302","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence - inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD012956.pub2-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"1303-10","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence - indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD012956.pub2-BIB0220|cit220","doi-asserted-by":"publisher","first-page":"1311-6","DOI":"10.1016\/j.jclinepi.2011.06.004","article-title":"GRADE guidelines: 9. Rating up the quality of evidence","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0221|cit221","doi-asserted-by":"publisher","first-page":"151-7","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0222|cit222","doi-asserted-by":"publisher","first-page":"158-72","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables - binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0223|cit223","doi-asserted-by":"publisher","first-page":"173-83","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles - continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0224|cit224","unstructured":"G\u00f8tzsche P Re: Why the Cochrane risk of bias tool should include funding source as a standard item. Response to JAC Sterne cochranelibrary.com\/editorial\/10.1002\/14651858.ED000076"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0225|cit225","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40263-017-0425-0","article-title":"A focused systematic review of pharmacological treatment for borderline personality disorder","volume":"31","author":"Hancock-Johnson","year":"2017","journal-title":"Central Nervous System Drugs"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0226|cit226","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1521\/pedi_2018_32_344","article-title":"Low vocational outcome among people diagnosed with borderline personality disorder during first admission to mental health services in Denmark: a nationwide 9-year register-based study","volume":"33","author":"Hastrup","year":"2019","journal-title":"Journal of Personality Disorders"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0227|cit227","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/acps.13094","article-title":"Societal costs of borderline personality disorders: a matched-controlled nationwide study of patients and spouses","volume":"140","author":"Hastrup","year":"2019","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0228|cit228","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/15622970701685224","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders","volume":"8","author":"Herpertz","year":"2007","journal-title":"World Journal of Biological Psychiatry"},{"issue":"7414","key":"10.1002\/14651858.CD012956.pub2-BIB0229|cit229","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0230|cit230","unstructured":"Higgins JPT Altmand DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston M, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0231|cit231","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0232|cit232","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1037\/0022-006X.56.6.885","article-title":"Inventory of interpersonal problems: psychometric properties and clinical applications","volume":"56","author":"Horowitz","year":"1988","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0234|cit234","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1176\/ps.2010.61.6.612","article-title":"Ten-year use of mental health services by patients with borderline personality disorder and with other axis II disorders","volume":"61","author":"H\u00f6rz","year":"2010","journal-title":"Psychiatric Services"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0235|cit235","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/JCP.0b013e3182217a69","article-title":"Differential effectiveness of antipsychotics in borderline personality disorder: Meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains","volume":"31","author":"Ingenhoven","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0236|cit236","doi-asserted-by":"publisher","first-page":"e522","DOI":"10.4088\/JCP.14com09522","article-title":"Pharmacotherapy for borderline patients: business as usual or by default?","volume":"76","author":"Ingenhoven","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD012956.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00115-021-01139-4","article-title":"Disease burden of borderline personality disorder: cost of illness, somatic comorbidity and mortality","volume":"92","author":"Jacobi","year":"2021","journal-title":"Nervenarzt"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0238|cit238","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2288-14-120","article-title":"Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Medical Research Methodology"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"issue":"11","key":"10.1002\/14651858.CD012956.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0241|cit241","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/YIC.0000000000000021","article-title":"Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices","volume":"29","author":"Knappich","year":"2014","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0242|cit242","doi-asserted-by":"publisher","first-page":"31","DOI":"10.21307\/sjcapp-2015-004","article-title":"Personality disorder in childhood and adolescence comes of age: a review of the current evidence and prospects for future research","volume":"3","author":"Kongerslev","year":"2015","journal-title":"Scandinavian Journal of Child and Adolescent Psychiatry and Psychology"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0243|cit243","first-page":"1","article-title":"Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project)","volume":"9","year":"2020","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0244|cit244","unstructured":"Kulkarni J Re: Your Request Email to: A Pathmanathan Ratnam"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0895-4356(94)00106-Z","article-title":"Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care","volume":"48","author":"Lau","year":"1995","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0246|cit246","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.biopsych.2006.09.019","article-title":"DSM-IV personality disorders in the National Comorbidity Survey Replication","volume":"62","author":"Lenzenweger","year":"2007","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0247|cit247","first-page":"343","article-title":"SAFTEE: a technique for the systematic assessment of side effects in clinical trials","volume":"22","author":"Levine","year":"1986","journal-title":"Psychopharmacology Bulletin"},{"issue":"9432","key":"10.1002\/14651858.CD012956.pub2-BIB0248|cit248","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(04)16770-6","article-title":"Borderline personality disorder","volume":"364","author":"Lieb","year":"2004","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1749-6632.1997.tb52367.x","article-title":"Behavioral treatments of suicidal behaviors: definitional obfuscation and treatment outcomes","volume":"836","author":"Linehan","year":"1997","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0250|cit250","first-page":"343","volume-title":"Essentials of Personality Disorders","author":"Links","year":"2009"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0251|cit251","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD012956.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00134-018-5293-7","article-title":"Industry sponsorship and research outcome: systematic review with meta-analysis","volume":"44","author":"Schroll Jeppe","year":"2018","journal-title":"Intensive care medicine"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0253|cit253","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1345\/aph.1E479","article-title":"Medication utilization patterns and methods of suicidality in borderline personality disorder","volume":"40","author":"Makela","year":"2006","journal-title":"Annals of Pharmacotherapy"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40479-015-0028-7","article-title":"Gender differences in aggression of borderline personality disorder","volume":"9","author":"Mancke","year":"2015","journal-title":"Borderline Personal Disord Emot Dysregul"},{"issue":"12(3)","key":"10.1002\/14651858.CD012956.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"e0171592","DOI":"10.1371\/journal.pone.0171592","article-title":"The value of psychological treatment for borderline personality disorder: Systematic review and cost offset analysis of economic evaluations","volume":"1","author":"Meuldijk","year":"2017","journal-title":"PLoS One"},{"issue":"9128","key":"10.1002\/14651858.CD012956.pub2-BIB0256|cit256","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"9193","key":"10.1002\/14651858.CD012956.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0258|cit258","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0259|cit259","doi-asserted-by":"publisher","first-page":"786-90","DOI":"10.1016\/B978-0-08-027080-7.50130-0","volume-title":"D\u00e9pression et Suicide: Aspects Medicaux, Psychologiques et Socio-Culturels","author":"Montgomery","year":"1983"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"655548","DOI":"10.3389\/fpsyt.2021.655548","article-title":"CD-11 personality disorders: utility and implications of the new model","volume":"12","author":"Mulder","year":"2021","journal-title":"Front Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/j.2051-5545.2010.tb00307.x","article-title":"Use of ICD-10 diagnoses in Danish psychiatric hospital-based services in 2001-2007","volume":"9","author":"Munk-J\u00f8rgensen","year":"2010","journal-title":"World Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD012956.pub2-BIB0262|cit262","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jclinepi.2013.02.004","article-title":"The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses","volume":"66","author":"Mustafa","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0263|cit263","unstructured":"Neuroscience-Based Nomenclature Neuroscience-Based Nomenclature, Second Edition-reivsed https:\/\/nbn2r.com\/search"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0264|cit264","unstructured":"Seroquel extended release (XR) for the management of borderline personality disorder (BPD) clinicaltrials.gov\/ct2\/show\/NCT00880919"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/1573400513666170612122034","article-title":"Understanding borderline personality disorder across sociocultural groups: findings, issues, and future directions","volume":"13","author":"Neacsiu","year":"2017","journal-title":"Current Psychiatry Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00127-020-01876-y","article-title":"Personality disorder prevalence and correlates in a whole of nation dataset","volume":"56","author":"Newton-Howes","year":"2021","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"8","key":"10.1002\/14651858.CD012956.pub2-BIB0267|cit267","doi-asserted-by":"publisher","first-page":"e0160515","DOI":"10.1371\/journal.pone.0160515","article-title":"Recovery from borderline personality disorder: a systematic review of the perspectives of consumers, clinicians, family and carers","volume":"11","author":"Ng","year":"2016","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0268|cit268","volume-title":"Clinical Practice Guideline for the Management of Borderline Personality Disorder","author":"National Health and Medical Research Council","year":"2013"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0269|cit269","unstructured":"National Institute for Health and Clinical Excellence Borderline personality disorder: recognition and management. NICE clinical guideline 78; 28 January 2009 Available at www.nice.org.uk\/guidance\/cg78"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0270|cit270","unstructured":"National Instiute for Health and Care Excellence (NICE) 2018 surveillance of personality disorders (NICE guidelines CG77 and CG78). Surveillance report. Published 19 July 2018 Available from www.nice.org.uk\/guidance\/cg78\/resources\/2018-surveillance-of-personality-disorders-nice-guidelines-cg77-and-cg78-4906490080\/chapter\/Surveillance-decision?tab=evidence."},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0271|cit271","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/pmh.1331","article-title":"Description and prediction of the income status of borderline patients over 10\u2009\u2009\u2009years of prospective follow-up","volume":"10","author":"Niesten","year":"2016","journal-title":"Personality and Mental Health"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0272|cit272","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1586\/14737167.4.5.581","article-title":"The truly remarkable universality of half a standard deviation: confirmation through another look","volume":"4","author":"Norman","year":"2004","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0273|cit273","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychires.2020.11.031","article-title":"Non-suicidal self-injury (NSSI) in adult psychiatric outpatients - a nationwide study","volume":"133","author":"Ose","year":"2021","journal-title":"Journal of Psychiatric Research"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0274|cit274","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/107319110100800409","article-title":"The Suicidal Behaviors Questionnaire-Revised (SBQ-R): validation with clinical and nonclinical samples","volume":"8","author":"Osman","year":"2001","journal-title":"Assessment"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0275|cit275","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1521\/pedi.16.3.283.22537","article-title":"Cross-system concordance of personality disorder diagnoses of DSM-IV and diagnostic criteria for research of ICD-10","volume":"16","author":"Ottosson","year":"2002","journal-title":"Journal of Personality Disorders"},{"issue":"10","key":"10.1002\/14651858.CD012956.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/0004867418791257","article-title":"Specialized psychotherapies for adults with borderline personality disorder: A systematic review and meta-analysis","volume":"52","author":"Oud","year":"2018","journal-title":"Aust N Z J Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0277|cit277","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0278|cit278","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.4088\/JCP.14com09441","article-title":"Why patients with severe personality disorders are overmedicated","volume":"76","author":"Paris","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD012956.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40263-021-00852-7","article-title":"Twenty-Year Trends in the Psychopharmacological Treatment of Outpatients with Borderline Personality Disorder: A Cross-Sectional Naturalistic Study in Spain.","volume":"35","author":"Pascual","year":"2021","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0280|cit280","doi-asserted-by":"publisher","first-page":"e512-8","DOI":"10.4088\/JCP.14m09228","article-title":"The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK Mental Health Services","volume":"76","author":"Paton","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0281|cit281","doi-asserted-by":"crossref","unstructured":"Comment on: \u201cPharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis\u201d CNS Drugs 35 1333 1334 https:\/\/doi.org\/10.1007\/s40263-021-00872-3","DOI":"10.1007\/s40263-021-00872-3"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0282|cit282","first-page":"229","article-title":"The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes","volume":"35","author":"Perez","year":"2007","journal-title":"Actas Espa\u00f1olas de Psiquiatr\u00eda"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0283|cit283","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2020"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0284|cit284","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/13651501.2019.1576904","article-title":"Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines","volume":"23","author":"Riffer","year":"2019","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"issue":"12","key":"10.1002\/14651858.CD012956.pub2-BIB0285|cit285","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.jaac.2012.09.018","article-title":"Mentalization-based treatment for self-harm in adolescents: a randomized controlled trial","volume":"51","author":"Rossouw","year":"2012","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0286|cit286","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S0010-440X(03)00147-0","article-title":"Borderline personality and psychotropic medication prescription in an outpatient psychiatry clinic","volume":"44","author":"Sansone","year":"2003","journal-title":"Comprehensive Psychiatry"},{"issue":"35","key":"10.1002\/14651858.CD012956.pub2-BIB0287|cit287","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technology Assessment"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0288|cit288","doi-asserted-by":"publisher","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"23-24","key":"10.1002\/14651858.CD012956.pub2-BIB0289|cit289","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3238\/arztebl.2019.0405","article-title":"Mortality and medical comorbidity in the severely mentally ill","volume":"116","author":"Schneider","year":"2019","journal-title":"Deutsches Arzteblatt International"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0290|cit290","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jama.273.5.408","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0291|cit291","doi-asserted-by":"publisher","first-page":"485-92","DOI":"10.1192\/bjp.bp.107.037903","article-title":"Olanzapine for the treatment of borderline personality disorder: variable dose, 12-week, randomised double-blind placebo-controlled study","volume":"193","author":"Schulz","year":"2008","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea Beverley","year":"2017","journal-title":"bmj"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/acps.12981","article-title":"Gender differences and similarities in aggression, suicidal behaviour, and psychiatric comorbidity in borderline personality disorder","volume":"139","author":"Sher","year":"2019","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0294|cit294","doi-asserted-by":"publisher","first-page":"e524-5","DOI":"10.4088\/JCP.14com09534","article-title":"Management and effectiveness of psychopharmacology in emotionally unstable and borderline personality disorder","volume":"76","author":"Silk","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0295|cit295","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40479-019-0106-3","article-title":"European guidelines for personality disorders: past, present and future","volume":"6","author":"Simonsen","year":"2019","journal-title":"Borderline Personality Disorder and Emotion Dysregulation"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0296|cit296","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1176\/appi.ajp.159.2.276","article-title":"Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder","volume":"159","author":"Skodol","year":"2002","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0297|cit297","first-page":"259-65","article-title":"The economic burden of personality disorders in mental health care","volume":"69","author":"Soeteman","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0298|cit298","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1521\/pedi.2008.22.3.259","article-title":"The burden of disease in personality disorders: diagnosis-specific quality of life","volume":"22","author":"Soeteman","year":"2008","journal-title":"Journal of Personality Disorders"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0299|cit299","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1521\/pedi.16.3.201.22542","article-title":"Childhood abuse as a risk factor for suicidal behavior in borderline personality disorder","volume":"16","author":"Soloff","year":"2002","journal-title":"Journal of Personality Disorders"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1176\/appi.ajp.2011.11091378","article-title":"Prospective predictors of suicidal behavior in borderline personality disorder at 6-year follow-up","volume":"169","author":"Soloff","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0301|cit301","volume-title":"Manual for the State-Trait Anger Expression Inventory","author":"Spielberger","year":"1988"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0302|cit302","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10802-011-9594-3","article-title":"Development of borderline personality disorder in adolescence and young adulthood: introduction to the special section","volume":"40","author":"Stepp","year":"2012","journal-title":"Journal of Abnormal Child Psychology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0303|cit303","doi-asserted-by":"crossref","unstructured":"Sterne JA Why the Cochrane risk of bias tool should not include funding source as a standard item Cochrane Database of Systematic Reviews 2013 12 ED000076 10.1002\/14651858.ED000076 24575440","DOI":"10.1002\/14651858.ED000076"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0304|cit304","unstructured":"Sterne JAC Egger M Moger D Boutron I Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0305|cit305","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1600-0447.2004.00466.x","article-title":"Aversive tension in patients with borderline personality disorder: a computer-based controlled field study","volume":"111","author":"Stiglmayr","year":"2005","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0306|cit306","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s11920-014-0534-0","article-title":"Pharmacotherapy for borderline personality disorder--current evidence and recent trends","volume":"17","author":"Stoffers","year":"2015","journal-title":"Current Psychiatry Reports"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0307|cit307","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012956","article-title":"Pharmacological interventions for people with borderline personality disorder","author":"Stoffers-Winterling","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD012956.pub2-BIB0308|cit308","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11920-020-01164-1","article-title":"Pharmacotherapy for borderline personality disorder: an update of published, unpublished and ongoing studies","volume":"22","author":"Stoffers-Winterling","year":"2020","journal-title":"Current Psychiatry Reports"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0309|cit309","unstructured":"Stoffers-Winterling J Cochrane Collaboration review - RCT of escitalopram in BPD Email to: E Coccaro"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0310|cit310","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1192\/bjp.162.3.299","article-title":"Long-term outcome in personality disorders","volume":"162","author":"Stone","year":"1993","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0311|cit311","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3109\/08039488.2013.841992","article-title":"Is ADHD an early stage in the development of borderline personality disorder?","volume":"68","author":"Storeb\u00f8","year":"2014","journal-title":"Nordic Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0312|cit312","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012955","article-title":"Psychological therapies for people with borderline personality disorder","author":"Storeb\u00f8\u00b8","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0313|cit313","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012955.pub2","article-title":"Psychological therapies for people with borderline personality disorder","author":"Storeb\u00f8","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0314|cit314","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12888-016-0939-x","article-title":"Prevalence rates of borderline personality disorder symptoms: a study based on the Netherlands Mental Health Survey and Incidence Study-2","volume":"16","author":"Ten Have","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0315|cit315","unstructured":"Thomas J Askie LM Berlin JA Elliott JH Ghersi D Simmonds M Takwoingi Y Tierney JF Prospective approaches to accumulating evidence. Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane 2021. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 Chapter 22 Wiley. Awailable from: www.training.cochrane.org\/handbook"},{"issue":"7","key":"10.1002\/14651858.CD012956.pub2-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00787-018-1257-2","article-title":"Psychotic symptoms in adolescents with borderline personality disorder features","volume":"28","author":"Thompson","year":"2019","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0317|cit317","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from meta-analysis?","volume":"38","author":"Thorlund","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0318|cit318","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1521\/pedi_2012_26_093","article-title":"Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning","volume":"28","author":"Tomko","year":"2014","journal-title":"Journal of Personality Disorders"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0319|cit319","doi-asserted-by":"publisher","first-page":"590-6","DOI":"10.1001\/archpsyc.58.6.590","article-title":"The prevalence of personality disorders in a community sample","volume":"58","author":"Torgersen","year":"2001","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0320|cit320","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/oxfordhb\/9780199735013.013.0009","volume-title":"The Oxford Handbook of Personality Disorders","author":"Torgersen","year":"2012"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0321|cit321","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1521\/pedi.2010.24.4.412","article-title":"Revised NESARC personality disorder diagnoses: gender, prevalence, and comorbidity with substance dependence disorders","volume":"24","author":"Trull","year":"2010","journal-title":"Journal of Personality Disorders"},{"issue":"3","key":"10.1002\/14651858.CD012956.pub2-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/0020764005057391","article-title":"The Social Functioning Questionnaire: a rapid and robust measure of perceived functioning","volume":"51","author":"Tyrer","year":"2005","journal-title":"International Journal of Social Psychiatry"},{"issue":"9969","key":"10.1002\/14651858.CD012956.pub2-BIB0323|cit323","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(14)61995-4","article-title":"Classification, assessment, prevalence, and effect of personality disorders","volume":"385","author":"Tyrer","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0324|cit324","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.eurpsy.2007.04.001","article-title":"The cost of borderline personality disorder: societal cost of illness in BPD-patients","volume":"22","author":"Van Asselt","year":"2007","journal-title":"European Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0325|cit325","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/JCP.0b013e31822c1636","article-title":"Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials","volume":"31","author":"Vita","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0326|cit326","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0327|cit327","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2288-9-86.","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0328|cit328","volume-title":"The ICD-10 Classification of Mental and Behavioral Disorders: Diagnostic Criteria for Research","author":"World Health Organisation","year":"1993"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0329|cit329","unstructured":"World Health Organisation ICD-11 for Mortality and Morbidity Statistics (Version: 05\/2021) icd.who.int\/browse11\/l-m\/en"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0330|cit330","unstructured":"WHO Collaborating Center for Drug Statistics ATC\/DDD Index 2021 https:\/\/www.whocc.no\/atc_ddd_index\/"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/978-1-4615-3008-4_15","volume-title":"Comprehensive Handbook of Psychopathology","author":"Widiger","year":"1993"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1521\/pedi.1998.12.2.95","article-title":"Invited essay: Sex biasesin the diagnosis of personality disorders","volume":"12","author":"Widiger","year":"1998","journal-title":"Journal of Personality Disorders"},{"issue":"7644","key":"10.1002\/14651858.CD012956.pub2-BIB0333|cit333","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0334|cit334","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamapsychiatry.2020.3598","article-title":"Association of borderline personality disorder criteria with suicide attempts: findings from the Collaborative Longitudinal Study of Personality Disorders over 10 years of follow-up","volume":"78","author":"Yen","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012956.pub2-BIB0335|cit335","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3109\/10673229809000330","article-title":"The pain of being borderline: dysphoric states specific to borderline personality disorder","volume":"6","author":"Zanarini","year":"1998","journal-title":"Harvard Review of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0336|cit336","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4088\/jcp.v65n0105","article-title":"Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years","volume":"65","author":"Zanarini","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD012956.pub2-BIB0337|cit337","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1176\/appi.ajp.161.11.2108","article-title":"Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission","volume":"161","author":"Zanarini","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0338|cit338","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1521\/pedi.2005.19.5.505","article-title":"The McLean Study of Adult Development (MSAD): overview and implications of the first six years of prospective follow-up","volume":"19","author":"Zanarini","year":"2005","journal-title":"Journal of Personality Disorders"},{"issue":"2","key":"10.1002\/14651858.CD012956.pub2-BIB0339|cit339","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1600-0447.2010.01543.x","article-title":"The 10-year course of psychosocial functioning among patients with borderline personality disorder and axis II comparison subjects","volume":"122","author":"Zanarini","year":"2010","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"5","key":"10.1002\/14651858.CD012956.pub2-BIB0340|cit340","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1176\/appi.ajp.2011.11101550","article-title":"Attainment and stability of sustained symptomatic remission and recovery among patients with borderline personality disorder and axis II comparison subjects: a 16-year prospective follow-up study","volume":"169","author":"Zanarini","year":"2012","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0341|cit341","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/JCP.0000000000000232","article-title":"Rates of psychotropic medication use reported by borderline patients and axis II comparison subjects over 16 years of prospective follow-up","volume":"35","author":"Zanarini","year":"2015","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012956.pub2-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.psychres.2018.01.034","article-title":"Description and prediction of time-to-attainment of excellent recovery for borderline patients followed prospectively for 20 years","volume":"262","author":"Zanarini","year":"2018","journal-title":"Psychiatry Research"},{"issue":"1","key":"10.1002\/14651858.CD012956.pub2-BIB0343|cit343","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005653","article-title":"Pharmacological interventions for people with borderline personality disorder","author":"Binks","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD012956.pub2-BIB0344|cit344","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005653.pub2","article-title":"Pharmacological interventions for borderline personality disorder","author":"Stoffers","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T07:44:23Z","timestamp":1702539863000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012956.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Developmental, Psychosocial and Learning Problems Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":344,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012956.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]}}}